Next 10 |
ZyVersa Therapeutics Inc. and Larkspur Health Acquisition Corp. Close Business Combination; ZyVersa Expected to Begin Trading on Nasdaq December 13, 2022 (Ticker "ZVSA") PR Newswire ZyVersa is a clinical stage biopharmaceutical company developing first-in-class product ca...
ZyVersa Therapeutics' CEO, Stephen C. Glover, and CCO, Karen A. Cashmere, Are Invited Speakers at the 4th Inflammasome Therapeutics Summit PR Newswire Annual Inflammasome Summit unites world renowned experts in inflammasome-targeted drug development and academia to s...
SEC Declares Form S-4 Registration Statement "Effective" for Proposed Business Combination of Larkspur Health Acquisition Corp., Inc. with ZyVersa Therapeutics, Inc. PR Newswire Special meeting of Larkspur stockholders scheduled for December 8, 2022 , to vote on ...
ZyVersa Therapeutics' CEO, Stephen C. Glover, Is Invited Speaker at BioFlorida 2022 Annual Conference PR Newswire Mr. Glover will be joining four other life science executives in a General Session titled, CEO Panel: Learn from the experts ZyVersa is a clinica...
ZyVersa Therapeutics and Larkspur Health Acquisition Corp. Announce Business Combination, Interim Financing and PIPE Investment Update PR Newswire Aggregate committed financing in support of the business combination now at $10.0 million ZyVersa and Larksp...
Data Published in Frontiers in Molecular Neuroscience Demonstrate That ZyVersa's Inflammasome ASC Inhibitor, IC 100, Is Effective in Reducing Brain Inflammation in a Preclinical Model of Aging PR Newswire Age-related chronic inflammation induced by activation of NLRP1 ...
Larkspur Health Acquisition Corp. Files Registration Statement on Form S-4 Regarding the Proposed Business Combination with ZyVersa Therapeutics PR Newswire BRIDGEWATER, N.J. and WESTON, Fla. , Aug. 15, 2022 /PRNewswire/ -- Larkspur Health Acquisition...
ZyVersa's Proprietary Inflammasome ASC Inhibitor's Differentiated Mechanism of Action Featured in Translational Research Paper PR Newswire IC 100, a novel monoclonal antibody inflammasome ASC inhibitor, targets multiple types of inflammasomes to block initiation and pe...
Clinical-stage biopharmaceutical firm ZyVersa Therapeutics will go public through a deal with SPAC Larkspur Health Acquisition ( NASDAQ: LSPR ). The combined firm will have an estimated pro forma enterprise valuation of ~$108.92M. Proceeds from the deal, estimated at ~...
ZyVersa Therapeutics to Become a Publicly Traded Biopharma Company via Merger with Larkspur Health Acquisition Corp. PR Newswire ZyVersa is a clinical stage biopharmaceutical company developing first-in-class product candidates to address significant unmet medical ne...
News, Short Squeeze, Breakout and More Instantly...
Larkspur Health Acquisition Corp. Company Name:
LSPR Stock Symbol:
NASDAQ Market:
ZyVersa Therapeutics Inc. and Larkspur Health Acquisition Corp. Close Business Combination; ZyVersa Expected to Begin Trading on Nasdaq December 13, 2022 (Ticker "ZVSA") PR Newswire ZyVersa is a clinical stage biopharmaceutical company developing first-in-class product ca...
ZyVersa Therapeutics' CEO, Stephen C. Glover, and CCO, Karen A. Cashmere, Are Invited Speakers at the 4th Inflammasome Therapeutics Summit PR Newswire Annual Inflammasome Summit unites world renowned experts in inflammasome-targeted drug development and academia to s...
SEC Declares Form S-4 Registration Statement "Effective" for Proposed Business Combination of Larkspur Health Acquisition Corp., Inc. with ZyVersa Therapeutics, Inc. PR Newswire Special meeting of Larkspur stockholders scheduled for December 8, 2022 , to vote on ...